A single dose of a commonly prescribed antidepressant suppresses Aβ production in the human central nervous system.
Changing ApoE levels in midlife influences Aβ pathology in mice, supporting an ApoE-oriented therapeutic strategy in Alzheimer’s disease.
New research suggests that α-synuclein comes in multiple strains, one of which seeds aggregation of tau.
Activating translation regulator eIF2alpha restores plasticity and memory in Alzheimer's models.
By looking for structural DNA variations in Alzheimer’s families, researchers identified 18 new genes that may play a role in AD pathology.
Removing a key component of the innate immune system worsens amyloid deposition but improves memory in mice that model Alzheimer's pathology.
Advances in RNA sequencing are shedding light on gene regulation and helping scientists make sense of data from genome-wide association studies.
Conventional wisdom says that excess excitation promotes degeneration of motor neurons in ALS, but a new study suggests excitability could be a good thing.
A mouse study suggests it may be possible to co-opt the liver to boost expression of neurotrophins in the brain.
Two studies strengthen the link between shut-eye and Alzheimer’s disease, and a mouse analysis of how the brain drains waste offers insight into the connection.
Meet ADCS-PACC, C3: Composites that measure subtle changes in cognition appear reliable, clearing the way for their use in clinical trials of people with presymptomatic AD.
New strategies may help find and retain participants for Alzheimer’s trials.
New research strengthens the idea that microglia do far more than scour the brain for emergencies.
Early dysfunction in Alzheimer’s may start in the lateral entorhinal cortex and spread from there to connected cortical brain regions.
Researchers have co-opted a molecular transport system to shuttle Aβ antibodies across the mouse blood-brain barrier. They predict the shuttle could smuggle a variety of drugs into the brain.